RATIONALE: Species of Salvia (sage) have a long-standing reputation in European medical herbalism, including for memory enhancement. In recent controlled trials, administration of sage extracts with established cholinergic properties improved cognitive function in young adults. OBJECTIVES: This randomised, placebo-controlled, double-blind, balanced, five-period crossover study investigated the acute effects on cognitive performance of a standardised extract of Salvia officinalis in older adults. MATERIALS AND METHODS:Twenty volunteers (>65 years of age, mean = 72.95) receivedfour active doses of extract (167, 333, 666 and 1332 mg) and a placebo with a 7-day wash-out period between visits. Assessment involved completion of the Cognitive Drug Research computerised assessment battery. On study days, treatments were administered immediately following a baseline assessment with further assessment at 1, 2.5, 4 and 6 h post treatment. RESULTS: Compared with the placebo condition (which exhibited the characteristic performance decline over the day), the 333-mg dose was associated with significant enhancement of secondary memory performance at all testing times. The same measure benefited to a lesser extent from other doses. There also were significant improvements to accuracy of attention following the 333-mg dose. In vitro analysis confirmed cholinesterase inhibiting properties for the extract. CONCLUSIONS: The overall pattern of results is consistent with a dose-related benefit to processes involved in efficient stimulus processing and/or memory consolidation rather than retrieval or working memory efficiency. These findings extend those of the memory-enhancing effects of Salvia extracts in younger populations and warrant further investigation in larger series, in other populations and with different dosing regimes.
RCT Entities:
RATIONALE: Species of Salvia (sage) have a long-standing reputation in European medical herbalism, including for memory enhancement. In recent controlled trials, administration of sage extracts with established cholinergic properties improved cognitive function in young adults. OBJECTIVES: This randomised, placebo-controlled, double-blind, balanced, five-period crossover study investigated the acute effects on cognitive performance of a standardised extract of Salvia officinalis in older adults. MATERIALS AND METHODS: Twenty volunteers (>65 years of age, mean = 72.95) received four active doses of extract (167, 333, 666 and 1332 mg) and a placebo with a 7-day wash-out period between visits. Assessment involved completion of the Cognitive Drug Research computerised assessment battery. On study days, treatments were administered immediately following a baseline assessment with further assessment at 1, 2.5, 4 and 6 h post treatment. RESULTS: Compared with the placebo condition (which exhibited the characteristic performance decline over the day), the 333-mg dose was associated with significant enhancement of secondary memory performance at all testing times. The same measure benefited to a lesser extent from other doses. There also were significant improvements to accuracy of attention following the 333-mg dose. In vitro analysis confirmed cholinesterase inhibiting properties for the extract. CONCLUSIONS: The overall pattern of results is consistent with a dose-related benefit to processes involved in efficient stimulus processing and/or memory consolidation rather than retrieval or working memory efficiency. These findings extend those of the memory-enhancing effects of Salvia extracts in younger populations and warrant further investigation in larger series, in other populations and with different dosing regimes.
Authors: I McKeith; T Del Ser; P Spano; M Emre; K Wesnes; R Anand; A Cicin-Sain; R Ferrara; R Spiegel Journal: Lancet Date: 2000-12-16 Impact factor: 79.321
Authors: D O Kennedy; G Wake; S Savelev; N T J Tildesley; E K Perry; K A Wesnes; A B Scholey Journal: Neuropsychopharmacology Date: 2003-10 Impact factor: 7.853
Authors: Xiaoxue Li; Jegason P Diviant; Sarah S Stith; Franco Brockelman; Keenan Keeling; Branden Hall; Jacob M Vigil Journal: Med Cannabis Cannabinoids Date: 2022-04-13
Authors: Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard Journal: Nat Rev Drug Discov Date: 2012-11 Impact factor: 84.694
Authors: Andrew Scholey; Anastasia Ossoukhova; Lauren Owen; Alvin Ibarra; Andrew Pipingas; Kan He; Marc Roller; Con Stough Journal: Psychopharmacology (Berl) Date: 2010-07-31 Impact factor: 4.530
Authors: Rachel H X Wong; Peter R C Howe; Janet Bryan; Alison M Coates; Jonathan D Buckley; Narelle M Berry Journal: Nutrients Date: 2012-05-03 Impact factor: 5.717